<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="12815" end="12819" sStart="12783" offset="32" sid="r7.1.use.v.0587" wn="1" wnkey="use%2:34:01::" annotator="brubin" text="A pulse-chase protocol was also used to study post-transcriptional regulation of APP metabolsm by statins (data not shown)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="8258" end="8269" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="For the detection of holoAPP and sAPP ? , samples were separated in 7.5% polyacrylamide gels, &lt;b&gt;transferred&lt;/b&gt; to nitrocellulose, and the proteins detected with either 369 (1:3,000 for holoAPP and C-terminal fragments) or 6E10 (1:1,000 for holoAPP or sAPP ? ), followed by incubation of the transfers with appropriate secondary anti-rabbit or anti-mouse antibodies." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="8735" end="8746" sStart="null" offset="0" sid="null" wn="2" wnkey="transfer%2:40:01::" annotator="carichter" text="For the detection of transfected ROCK1 proteins, samples were immunoprecipitated with 2 ?g of anti-Myc antibody, separated in 5% polyacrylamide gels, &lt;b&gt;transferred&lt;/b&gt;, and the proteins detected with anti-ROCK1 antibody (1:1,000 dilution)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="9719" end="9730" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="carichter" text="After washing twice with 1% Triton/PBS, and then twice with PBS, samples were boiled in sample buffer for 3 min, separated in a 7.5% polyacrylamide gel, and &lt;b&gt;transferred&lt;/b&gt; to nitrocellulose." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="25688" end="25693" sStart="null" offset="69" sid="r7.trace.v.0331" wn="2147483645" wnkey="null" annotator="brubin" text="Most of this shedding is catalyzed by the ?-secretase pathway, but a trace amount (&lt;5% [49]) is catalyzed by ?-secretase/?-site APP cleaving enzyme [50]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14394" end="14400" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="veweser" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13657" end="13663" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="veweser" text=", at 15 or 75 min chase, &lt;b&gt;mature&lt;/b&gt; APP in the presence of statin was approximately 310% of the level of immature APP at t = 0 versus a control [vehicle treatment] of 150% of the level of immature APP at t = 0; also, at t = 30 min, the relative percent values for drug versus vehicle were 380% and 200%, respectively)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14345" end="14351" sStart="null" offset="0" sid="null" wn="1" wnkey="mature%2:30:00::" annotator="veweser" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13212" end="13218" sStart="null" offset="0" sid="null" wn="1" wnkey="mature%2:30:00::" annotator="veweser" text="Typical maturation and half-life of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP were observed, as was subsequent release of sAPP ? [5,29]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14587" end="14593" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="veweser" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13545" end="13551" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="veweser" text="In the presence of either atorvastatin or simvastatin, the time course of maturation and release perfectly paralleled that observed in the absence of either drug, except that the fractional content of cellular &lt;b&gt;mature&lt;/b&gt; holoAPP was approximately 2-fold greater in the presence of drug (i.e." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14587" end="14593" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="rstandig" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13545" end="13551" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="rstandig" text="In the presence of either atorvastatin or simvastatin, the time course of maturation and release perfectly paralleled that observed in the absence of either drug, except that the fractional content of cellular &lt;b&gt;mature&lt;/b&gt; holoAPP was approximately 2-fold greater in the presence of drug (i.e." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14587" end="14593" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="jeneale" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13545" end="13551" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="jeneale" text="In the presence of either atorvastatin or simvastatin, the time course of maturation and release perfectly paralleled that observed in the absence of either drug, except that the fractional content of cellular &lt;b&gt;mature&lt;/b&gt; holoAPP was approximately 2-fold greater in the presence of drug (i.e." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14394" end="14400" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13657" end="13663" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text=", at 15 or 75 min chase, &lt;b&gt;mature&lt;/b&gt; APP in the presence of statin was approximately 310% of the level of immature APP at t = 0 versus a control [vehicle treatment] of 150% of the level of immature APP at t = 0; also, at t = 30 min, the relative percent values for drug versus vehicle were 380% and 200%, respectively)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14345" end="14351" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13212" end="13218" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Typical maturation and half-life of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP were observed, as was subsequent release of sAPP ? [5,29]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14587" end="14593" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13545" end="13551" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="In the presence of either atorvastatin or simvastatin, the time course of maturation and release perfectly paralleled that observed in the absence of either drug, except that the fractional content of cellular &lt;b&gt;mature&lt;/b&gt; holoAPP was approximately 2-fold greater in the presence of drug (i.e." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14394" end="14400" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13657" end="13663" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text=", at 15 or 75 min chase, &lt;b&gt;mature&lt;/b&gt; APP in the presence of statin was approximately 310% of the level of immature APP at t = 0 versus a control [vehicle treatment] of 150% of the level of immature APP at t = 0; also, at t = 30 min, the relative percent values for drug versus vehicle were 380% and 200%, respectively)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14345" end="14351" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13212" end="13218" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Typical maturation and half-life of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP were observed, as was subsequent release of sAPP ? [5,29]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14587" end="14593" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13545" end="13551" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="In the presence of either atorvastatin or simvastatin, the time course of maturation and release perfectly paralleled that observed in the absence of either drug, except that the fractional content of cellular &lt;b&gt;mature&lt;/b&gt; holoAPP was approximately 2-fold greater in the presence of drug (i.e." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="14587" end="14593" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="bpassonneau" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular &lt;b&gt;mature&lt;/b&gt; holoAPP and causes retarded conversion of &lt;b&gt;mature&lt;/b&gt; holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of &lt;b&gt;mature&lt;/b&gt; cellular holoAPP." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020018.anc" start="13545" end="13551" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="bpassonneau" text="In the presence of either atorvastatin or simvastatin, the time course of maturation and release perfectly paralleled that observed in the absence of either drug, except that the fractional content of cellular &lt;b&gt;mature&lt;/b&gt; holoAPP was approximately 2-fold greater in the presence of drug (i.e." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="36055" end="36061" sStart="null" offset="164" sid="null" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="To date, however, this mechanism is not supported by data from human clinical trials, where statin administration has shown no consistent effect on levels of circulating or cerebrospinal fluid A? [73]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="14577" end="14583" sStart="null" offset="335" sid="r9.level.n.0353" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="Secretory maturation toxicity is one possible mechanism for elevated levels of intracellular mature holoAPP and causes retarded conversion of mature holoAPP to sAPP ? . This pattern was not observed following statin treatment, excluding maturation toxicity as a mechanism underlying the altered levels of mature cellular holoAPP." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="36055" end="36061" sStart="null" offset="164" sid="null" wn="1" wnkey="level%1:07:00::" annotator="sophiavv" text="To date, however, this mechanism is not supported by data from human clinical trials, where statin administration has shown no consistent effect on levels of circulating or cerebrospinal fluid A? [73]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="36055" end="36061" sStart="null" offset="164" sid="null" wn="1" wnkey="level%1:07:00::" annotator="cgozo" text="To date, however, this mechanism is not supported by data from human clinical trials, where statin administration has shown no consistent effect on levels of circulating or cerebrospinal fluid A? [73]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="36055" end="36061" sStart="null" offset="164" sid="null" wn="1" wnkey="level%1:07:00::" annotator="brubin" text="To date, however, this mechanism is not supported by data from human clinical trials, where statin administration has shown no consistent effect on levels of circulating or cerebrospinal fluid A? [73]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="36055" end="36061" sStart="null" offset="164" sid="null" wn="" wnkey="null" annotator="bpassonneau" text="To date, however, this mechanism is not supported by data from human clinical trials, where statin administration has shown no consistent effect on levels of circulating or cerebrospinal fluid A? [73]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="36055" end="36061" sStart="null" offset="164" sid="null" wn="2" wnkey="level%1:26:01::" annotator="anfahmy" text="To date, however, this mechanism is not supported by data from human clinical trials, where statin administration has shown no consistent effect on levels of circulating or cerebrospinal fluid A? [73]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="17531" end="17537" sStart="null" offset="163" sid="r9.level.n.0846" wn="1" wnkey="level%1:07:00::" annotator="anfahmy" text="Co-treatment of cells with PO plus either atorvastatin or simvastatin caused stimulation of sAPP ? shedding to levels greater than the maximal levels of shedding achievable with inhibition of endocytosis using PO alone or with maximal doses of either statin alone ( p &lt; 0.05)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="26162" end="26166" sStart="null" offset="79" sid="r9.late.j.0638" wn="6" wnkey="late%3:00:02::" annotator="anfahmy" text="HoloAPP levels are likely limiting at one or more sorting steps in the late secretory pathway, since activated sAPP ? shedding is apparently accompanied by diminished generation of sAPP ? [51]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="27723" end="27731" sStart="null" offset="25" sid="r11.function.n.0842" wn="2" wnkey="function%1:07:00::" annotator="anfahmy" text="Therefore, one important function for ?- and/or ?-secretase processing of APP may be the eventual generation of AICD." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="15374" end="15378" sStart="null" offset="742" sid="r9.fold.v.0649" wn="2147483645" wnkey="null" annotator="veweser" text="Instead, the pattern that we observed raises the possibility that statins, presumably via isoprenoids (given the reversibility with mevalonate), as discussed in the next section, may alter sorting of cellular holoAPP, diverting holoproteins away from terminal degradation in the endosomal/lysosomal pathway and into the constitutive secretory pathway that generates sAPP ? . However, the fold effect on reduced intracellular turnover in the endosomal/lysosomal pathway (or sorting out of the endosomal/lysosomal pathway and into the constitutive secretory/shedding pathway) is apparently insufficient to explain the fold effect on sAPP ? generation (2-fold for the former, vs 3- to 4-fold for the latter), indicating a contribution from a downstream site in the processing pathway." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="15070" end="15074" sStart="null" offset="438" sid="r9.fold.v.0533" wn="2147483645" wnkey="null" annotator="veweser" text="Instead, the pattern that we observed raises the possibility that statins, presumably via isoprenoids (given the reversibility with mevalonate), as discussed in the next section, may alter sorting of cellular holoAPP, diverting holoproteins away from terminal degradation in the endosomal/lysosomal pathway and into the constitutive secretory pathway that generates sAPP ? . However, the fold effect on reduced intracellular turnover in the endosomal/lysosomal pathway (or sorting out of the endosomal/lysosomal pathway and into the constitutive secretory/shedding pathway) is apparently insufficient to explain the fold effect on sAPP ? generation (2-fold for the former, vs 3- to 4-fold for the latter), indicating a contribution from a downstream site in the processing pathway." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="15328" end="15332" sStart="null" offset="696" sid="r9.fold.v.0235" wn="2147483645" wnkey="null" annotator="cgozo" text="Instead, the pattern that we observed raises the possibility that statins, presumably via isoprenoids (given the reversibility with mevalonate), as discussed in the next section, may alter sorting of cellular holoAPP, diverting holoproteins away from terminal degradation in the endosomal/lysosomal pathway and into the constitutive secretory pathway that generates sAPP ? . However, the fold effect on reduced intracellular turnover in the endosomal/lysosomal pathway (or sorting out of the endosomal/lysosomal pathway and into the constitutive secretory/shedding pathway) is apparently insufficient to explain the fold effect on sAPP ? generation (2-fold for the former, vs 3- to 4-fold for the latter), indicating a contribution from a downstream site in the processing pathway." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="15406" end="15410" sStart="null" offset="774" sid="r9.fold.v.0302" wn="" wnkey="null" annotator="anfahmy" text="Instead, the pattern that we observed raises the possibility that statins, presumably via isoprenoids (given the reversibility with mevalonate), as discussed in the next section, may alter sorting of cellular holoAPP, diverting holoproteins away from terminal degradation in the endosomal/lysosomal pathway and into the constitutive secretory pathway that generates sAPP ? . However, the fold effect on reduced intracellular turnover in the endosomal/lysosomal pathway (or sorting out of the endosomal/lysosomal pathway and into the constitutive secretory/shedding pathway) is apparently insufficient to explain the fold effect on sAPP ? generation (2-fold for the former, vs 3- to 4-fold for the latter), indicating a contribution from a downstream site in the processing pathway." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="2860" end="2866" sStart="null" offset="31" sid="r8.family.n.0847" wn="3" wnkey="family%1:14:04::" annotator="brubin" text="Some members of the Rho GTPase family exert their actions through modulation of protein kinase activities." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="2665" end="2669" sStart="null" offset="113" sid="r7.1.face.n.0161" wn="6" wnkey="face%1:15:00::" annotator="veweser" text="These posttranslational lipid modifications are essential for attachment of the GTPases to the cytosolic face of intracellular vesicles and/or to the cytosolic leaflet of the plasma membrane, thereby specifying subcellular targets for GTPase action(s)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="20861" end="20868" sStart="null" offset="194" sid="r10.control.n.0167" wn="4" wnkey="control%1:09:02::" annotator="cgozo" text="Conversely, DN ROCK1 alone activated shedding of sAPP ? . Cellular levels of holoAPP were not affected by transfection (Figure 5; p &lt; 0.05 versus GFP control)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="27132" end="27144" sStart="null" offset="62" sid="r11.combination.n.0904" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Mice with double and triple null mutations in various combinations of APP, APP-like protein 1, and APP-like protein 2 are now being created, in search of evidence for a definitive function for APP." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="18685" end="18696" sStart="null" offset="59" sid="r11.combination.n.0848" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="FTI-1 increased the shedding of sAPP ? , but the combination of a statin plus FTI-1 increased sAPP ? shedding to levels greater than those achievable by using either compound alone (Figure 3; p &lt; 0.05)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="36812" end="36820" sStart="null" offset="282" sid="r11.benefit.n.0686" wn="2" wnkey="benefit%1:07:00::" annotator="anfahmy" text="Identification of the role of the Rho/ROCK pathway in regulating ?-secretase provides a new avenue for its therapeutic activation, even though the potential relevance of atorvastatin-mediated ROCK1 inhibition in neurons may not explain the apparent clinical benefits of the drug." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="11515" end="11522" sStart="null" offset="162" sid="r11.absence.n.1000" wn="1" wnkey="absence%1:26:00::" annotator="vebatchelder" text="In order to refine our localization of the subcellular target of statin action, we evaluated the steady-state levels of cell-surface APP (csAPP) in the absence or presence of statins." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020018.anc" start="30800" end="30804" sStart="null" offset="25" sid="r11.able.j.0271" wn="1" wnkey="able%3:00:00::" annotator="vebatchelder" text="Further, we were able to demonstrate that ?-secretase activity could be modulated by molecules further upstream in the isoprenoid pathway (see Figure 7)." />
  </sentences>
</list>